ArticleJournal of nanobiotechnology2023
Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease.
Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 110 citations in OpenAlex.
- Triptolide loaded cerium oxide nanozyme based oral nanoplatform for targeted colitis therapy.International journal of pharmaceutics: X · 2026Article
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- Advances of oral micro- and nanomedicines for modulating intestinal barriers in the treatment of intestinal diseases.Acta pharmaceutica Sinica. B · 2026Review
- Application of cerium dioxide nanoparticles in the treatment of intervertebral disc degeneration induced by oxidative stress.Journal of translational medicine · 2026Article
- Size-dependent ruthenium/ceria nanozymes synchronize catalytic ROS scavenging and electrostatic mtDNA sequestration for periodontitis therapy.Journal of nanobiotechnology · 2026Article
- Biomimetic nanoplatform M-MPDA@CeO2 coated with macrophage membrane in acute lung injury: characterization and function evaluation.Journal of translational medicine · 2026Article
- Multifunctional Cu-doped MnMaterials today. Bio · 2026Article
- Renal-Targeted Inulin-Based Gd/Zn Hybrids for Safe MRI Contrast and Early Fibrosis Mitigation.International journal of nanomedicine · 2026Article
- All Nanozyme-Based Cascade Reactions for Biomedical Applications: from Self-Cascading Nanozyme to Immobilized Cascade Nanozyme.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Discoidin Domain Receptor 1 in Colonic Epithelial Cells: A Paracrine Driver of Colonic Fibrosis.Current pharmaceutical biotechnology · 2026Article
- Nanoparticle-Based Drug Delivery Systems for Periodontitis: Antibacterial, Immunomodulatory, and Regenerative Strategies.International journal of nanomedicine · 2026Review
- A ROS-responsive nanocarrier co-delivering cerium nanozymes and thalidomide for synergistic ulcerative colitis therapy.Materials today. Bio · 2025Article
- Biomedical Applications of Nanozymes: An Enzymology Perspective.Angewandte Chemie (International ed. in English) · 2025Review
- New advances of nanozymes for the diagnosis and treatment of digestive system diseases (Review).International journal of molecular medicine · 2025Review
- Electron-injected Pd@CeOJournal of nanobiotechnology · 2025Article
- Carrier-Free Nanocapsule with Dual-Target Capacity for Synergistically Restoring Inflammatory Microenvironment and Microbiota Dysbiosis in Colitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Pathogenesis guided application of nanozymes in the treatment of inflammatory bowel disease.Materials today. Bio · 2025Review
- Microalgal-enhanced cerium oxide nanotherapeutics for alleviating inflammatory bowel disease via scavenging reactive oxygen species and modulating gut microbiota in colitis.Materials today. Bio · 2025Article
- Review
- Adipose-derived small extracellular vesicle miR-146a-5p targets Fbx32 to regulate mitochondrial autophagy and delay aging in skeletal muscle.Journal of nanobiotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundInflammatory bowel disease (IBD) is a chronic nonspecific disease with unknown etiology. Currently, the anti-inflammatory therapeutic approaches have achieved a certain extent of effects in terms of inflammation alleviation. Still, the final pathological outcome of intestinal fibrosis has not been effectively improved yet.
resultsIn this study, dextran-coated cerium oxide (D-CeO
conclusionWe introduced cerium oxide nanozyme as a novel therapeutic approach with computed tomography (CT)-guided anti-inflammatory and anti-fibrotic therapy for the management of IBD. Collectively, without appreciable systemic toxicity, D-CeO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.